Retatrutide (often called “Reta”) is an investigational peptide developed for weight loss, obesity, and metabolic health. It is known as a triple agonist because it targets three hormone receptors at the same time: GLP-1, GIP, and glucagon receptors. This combination is designed to help reduce appetite, improve blood sugar control, increase feelings of fullness, and boost the body’s calorie-burning ability. Potential benefits being studied include: Significant weight loss Reduced appetite and food cravings Improved insulin sensitivity Better blood sugar regulation Increased fat oxidation and energy expenditure Possible improvements in metabolic health and fatty liver disease Commonly reported side effects may include: Nausea Vomiting Diarrhea Constipation Fatigue Stomach discomfort Temporary increases in heart rate Retatrutide has shown impressive weight-loss results in clinical trials, but it is still under investigation and is not currently FDA-approved. Researchers continue studying its long-term safety and effectiveness. vial arrives in crystal form. for research purposes only.
